MX2022002293A - Péptidos recombinantes inmunotolerantes similares a la elastina y métodos de uso. - Google Patents
Péptidos recombinantes inmunotolerantes similares a la elastina y métodos de uso.Info
- Publication number
- MX2022002293A MX2022002293A MX2022002293A MX2022002293A MX2022002293A MX 2022002293 A MX2022002293 A MX 2022002293A MX 2022002293 A MX2022002293 A MX 2022002293A MX 2022002293 A MX2022002293 A MX 2022002293A MX 2022002293 A MX2022002293 A MX 2022002293A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- elastin
- recombinant polypeptides
- recombinant peptides
- disclosed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962890936P | 2019-08-23 | 2019-08-23 | |
| PCT/US2020/040230 WO2021040881A1 (en) | 2019-08-23 | 2020-06-30 | Immune tolerant elastin-like recombinant peptides and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022002293A true MX2022002293A (es) | 2022-06-02 |
Family
ID=74683687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022002293A MX2022002293A (es) | 2019-08-23 | 2020-06-30 | Péptidos recombinantes inmunotolerantes similares a la elastina y métodos de uso. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220280615A1 (enExample) |
| EP (1) | EP4017541A4 (enExample) |
| JP (1) | JP2022546384A (enExample) |
| KR (1) | KR20220103916A (enExample) |
| CN (1) | CN114667160A (enExample) |
| BR (1) | BR112022003498A2 (enExample) |
| CA (1) | CA3149274A1 (enExample) |
| IL (1) | IL290839A (enExample) |
| MX (1) | MX2022002293A (enExample) |
| WO (1) | WO2021040881A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113444182B (zh) * | 2021-06-22 | 2022-07-19 | 四川大学华西医院 | 一种靶向递送IgG类抗体的融合蛋白载体及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006110292A2 (en) * | 2005-03-25 | 2006-10-19 | The Regents Of The University Of California | Temperature-triggered immobilization and purification of antibodies |
| JP2014529997A (ja) * | 2011-09-23 | 2014-11-17 | ウニヴェルズィテート シュトゥットガルト | 免疫グロブリン結合ドメインを使った血清中半減期延長 |
| JP6924151B2 (ja) * | 2015-05-29 | 2021-08-25 | ユニヴァーシティー オブ ユタ リサーチ ファウンデーション | 免疫寛容及び非免疫寛容エラスチン様組換えペプチドならびに使用方法 |
| EP3691693A4 (en) * | 2017-10-06 | 2021-08-25 | University Of Utah Research Foundation | FUSION PROTEIN FOR TARGETED THERAPY OF AUTOIMMUNE DISEASE |
| WO2019144309A1 (en) * | 2018-01-24 | 2019-08-01 | Beijing Percans Oncology Co. Ltd. | Cytokine Fusion Proteins |
-
2020
- 2020-06-30 MX MX2022002293A patent/MX2022002293A/es unknown
- 2020-06-30 EP EP20856151.4A patent/EP4017541A4/en not_active Withdrawn
- 2020-06-30 WO PCT/US2020/040230 patent/WO2021040881A1/en not_active Ceased
- 2020-06-30 JP JP2022512869A patent/JP2022546384A/ja not_active Ceased
- 2020-06-30 US US17/637,639 patent/US20220280615A1/en not_active Abandoned
- 2020-06-30 CA CA3149274A patent/CA3149274A1/en active Pending
- 2020-06-30 KR KR1020227009130A patent/KR20220103916A/ko not_active Ceased
- 2020-06-30 CN CN202080074005.2A patent/CN114667160A/zh active Pending
- 2020-06-30 BR BR112022003498A patent/BR112022003498A2/pt unknown
-
2022
- 2022-02-23 IL IL290839A patent/IL290839A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4017541A1 (en) | 2022-06-29 |
| JP2022546384A (ja) | 2022-11-04 |
| IL290839A (en) | 2022-04-01 |
| KR20220103916A (ko) | 2022-07-25 |
| CA3149274A1 (en) | 2021-03-04 |
| BR112022003498A2 (pt) | 2022-08-16 |
| US20220280615A1 (en) | 2022-09-08 |
| EP4017541A4 (en) | 2023-08-23 |
| WO2021040881A1 (en) | 2021-03-04 |
| CN114667160A (zh) | 2022-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019502484A1 (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| PH12021550802A1 (en) | Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof | |
| NZ713461A (en) | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer | |
| MX2021008207A (es) | Proteínas de fusión multifuncionales y usos de las mismas. | |
| RU2016122957A (ru) | Способы применения интерлейкина-10 для лечения заболеваний и расстройств | |
| CY1118373T1 (el) | Υψηλης συγκεντρωσης υγρες μορφοποιησεις anti-tnfa αντισωματος | |
| EA202091754A1 (ru) | Пептиды и комбинации пептидов неканонического происхождения для применения в иммунотерапии различных видов рака | |
| EP4623992A3 (en) | Antibodies specifically binding to human il-1r7 | |
| IN2014KN01715A (enExample) | ||
| EA201992664A2 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака | |
| EA201791925A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей | |
| JP2017518303A5 (enExample) | ||
| AU2015269210A8 (en) | Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof | |
| WO2017096327A3 (en) | Compositions and methods for reducing immune responses against chimeric antigen receptors | |
| ZA202107947B (en) | Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer | |
| SA521421371B1 (ar) | لقاحات الببتيد | |
| IL240695B1 (en) | NME inhibitors and methods of using NME inhibitors | |
| WO2017180988A3 (en) | Fgf21 c-terminal peptide optimization | |
| EA201790341A1 (ru) | Анти-ск8 антитела для применения в лечении рака | |
| NZ610487A (en) | Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins | |
| PH12021551174A1 (en) | Novel folr1 specific binding proteins for cancer diagnosis and treatment | |
| MX2024001808A (es) | Proteinas que desacoplan la citotoxicidad tumoral mediada por celulas t de la liberacion de citoquinas proinflamatorias. | |
| WO2020086479A9 (en) | Dosing | |
| BR112022003498A2 (pt) | Peptídeos recombinantes do tipo elastina imunotolerantes e métodos de uso | |
| EA202190572A1 (ru) | Иммунотерапия раковых заболеваний рестриктированными по a*01 пептидами и комбинациями пептидов и относящиеся к ней способы |